To obtain a new compound having 5α-reductase inhibiting activities, especially both Type I and Type II 5α-reductase inhibiting activities and useful for treating benign prostatomegaly, male pattern alopecia, common acne or the like, and further to obtain the subject inhibitor containing the compound.
This 5α-reductase inhibitor is the one of formula I (R and R1 are each H or form a bond with each other; R2 is H or a 1-3C alkyl; R3 is methyl or ethyl; R4 and X-R5 occupy each one of 7-, 8-and 9 positions, and R4 is H, a halo, methyl or the like, and R5 is phenyl, naphthalenyl, pyridyl or the like) or a pharmaceutically acceptable salt thereof, e.g. (+)-(4aR)-(10bR)-4- methyl-8-(4-ethyl-2-benzothiazolylthio)-10b-methyl-1,2,3,4,4a,5,6,10b- octahydrobenzo[f]quinolin-3-one. The compound of formula I is obtained, for example, by reacting an intermediate product of formula II (L is an eliminable group) with an active compound of the formula X-R5.
KEBIN RII HIIRU
TOOMASU JIYOZEFU KURESU
RORETSUTA EIMESU MAKAIDO
BUREIKU RII NOIBAUAA
BINSENTO PATORITSUKU ROTSUKO
JIEIMUZU PATORITSUKU UEPUSHIIK
Next Patent: IMMUNOSUPPRESSIVE CYCLOLIGNAN DERIVATIVE